Live attenuated rubella vaccine is used for vaccination. Temperature-sensitive (ts) phenotype was proved for almost all rubella vaccine strains, and the acquisition of the ts phenotype during cold adaptation was strongly correlated with the attenuation of the wild-type viruses. Nevertheless, the molecular mechanisms of the attenuation have been insufficiently understood for rubella virus. Study ofthese mechanisms, identifying genotypic markers of attenuation, which together with the sequence analyses could be used for genetic stability control of vaccine strains, is still of current interest. In this work, we determined nearly complete genome sequences of attenuated (ca) and the wildtype progenitor (wt) of the rubella virus strain C-77 isolated in Russia. Possible genetic determinants of attenuation were detected. Thus, 13 nucleotide differences leading to 6 amino acid substitutions were found. Four amino acid substitutions were found to be almost unique. Special consideration should be given to Tyr1042Cys substitution in the protease domain of C-77 strain, because it most probably plays the crucial role in acquisition of ts-phenotype.

2010-07-01·Vaccine3区 · 医学

Robustness testing of live attenuated rubella vaccine potency assay using fractional factorial design of experiments

3区 · 医学

Article

作者: Ivana Zadro ; Beata Halassy ; Nediljko Pavlović ; Leonida Kutle ; Marko Dorotić ; Marijana Kapustić

The potency assay for the freeze-dried live attenuated rubella vaccine is a cell culture based biological assay. The aim of our study was to perform the robustness testing of the rubella vaccine potency assay prior to validation. Seven intra-assay operating conditions that could have an effect on the assay performance were identified and their influence on the overall assay variability investigated by fractional factorial design of experiments (DoE). The robustness testing through DoE showed that the rubella vaccine potency assay is a robust assay. Critical operating conditions can be identified using DoE, which indicates that it is a suitable approach in bioassay robustness studies.

1995-12-01·Journal of Medical Virology4区 · 医学

Persistent rubella infection after erroneous vaccination in an immunocompromised patient with acute lymphoblastic leukemia in remission

4区 · 医学

Article

作者: R. Geiger ; B. Sölder ; G. Enders ; M. Sailer ; F. M. Fink

AbstractA 16‐year‐old male patient with acute lymphoblastic leukemia in complete remission and on maintenance treatment with weekly oral rnethotrexate and daily oral 6‐mercaptopurine for 3 months was immunized in error with the WI‐RA 27/3‐HDC live attenuated rubella vaccine. Increasing rubella HAI antibodies were noted from 3 to 7 months post‐vaccination as well as high levels of IgM antibody up to 8 months in three different tests. High HAI antibody titers persisted for 12–18 months after vaccination. Persisting rubella virus was indicated by PCR detection of rubella‐specific nucleic acid in whole blood, non‐stimulated and stimulated mononuclear cells 8 months following vaccination. Further attempts to detect rubella virus RNA in two subsequent blood samples were negative. Since acute arthritis and arthralgia occurred in the second month (days 51–63) after vaccination, antileukemic chemotherapy had to be interrupted. Evidence of higher risk for chronic or relapsing rubella‐associated arthropathy in immunologically compromised patients and the need to interrupt antileukemic chemotherapy should warrant imrnunoprophylaxis with polyvalent immune globulin in rubella‐susceptible patients who are immunocompromised. © Wiley‐Liss, Inc.

100 项与 DRIED LIVE ATTENUATED RUBELLA VACCINE(Takeda Pharmaceutical) 相关的药物交易

登录后查看更多信息